Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29497765 | 0.87 | HSD17B10 (0.59) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL27987524 | 0.79 | CYP11B1 (0.44) | SMN1; SMN2KMT2AMEN1LMNACYP1A2 | |
| SCHEMBL14835973 | 0.78 | MEN1 (0.67) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13195822 | 0.74 | KMT2A (0.71) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL14808444 | 0.74 | KMT2A (1.00) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9713689 | 0.73 | NPSR1 (1.00) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL9823523 | 0.73 | KMT2A (0.70) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12291744 | 0.73 | KMT2A (0.75) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL1133966 | 0.72 | KMT2A (0.58) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL426545 | 0.72 | KMT2A (0.58) | NPSR1HSD17B10SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220096370-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2022-03-31 | — | — | US | disclosed |
| US-11135153-B2 | High penetration composition and uses thereof | TECHFIELDS PHARMA CO., LTD. (CN) | 2021-10-05 | — | — | US | disclosed |
| US-20170151337-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | PREMIER RESEARCH INTERNATIONAL, LLC | 2017-06-01 | — | — | US | disclosed |
| US-20090221703-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | TECHFIELDS PHARMA CO., LTD. (CN) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221703-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | ABCG2, ALPP, SLC7A1 | NPSR1 873/4885HSD17B10 397/4885SMN1; SMN2 3712/4885 |
| US-20220096370-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | ABCG2, ALPP, SLC7A1 | NPSR1 873/4885HSD17B10 397/4885SMN1; SMN2 3712/4885 |
| US-11135153-B2 | High penetration composition and uses thereof | ABCG2, ALPP, SLC7A1 | NPSR1 873/4885HSD17B10 397/4885SMN1; SMN2 3712/4885 |
| US-20170151337-A1 | HIGH PENETRATION COMPOSITION AND USES THEREOF | ABCG2, ALPP, SLC7A1 | NPSR1 873/4885HSD17B10 397/4885SMN1; SMN2 3712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.